U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C27H23N5O4.H2O
Molecular Weight 981.0205
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PRANLUKAST HEMIHYDRATE

SMILES

O.O=C(NC1=CC=CC2=C1OC(=CC2=O)C3=NN=NN3)C4=CC=C(OCCCCC5=CC=CC=C5)C=C4.O=C(NC6=CC=CC7=C6OC(=CC7=O)C8=NN=NN8)C9=CC=C(OCCCCC%10=CC=CC=C%10)C=C9

InChI

InChIKey=MSXTUBJFNBZPGC-UHFFFAOYSA-N
InChI=1S/2C27H23N5O4.H2O/c2*33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18;/h2*1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32);1H2

HIDE SMILES / InChI

Description

Pranlukast is an antagonist of cysteinyl leukotriene receptor-1 antagonist. It is marketed in Japan by Ono Pharmaceuticals under trademark ONON for the treatment of bronchial asthma and allergic rhinitis as capsules and dry syrup for pediatric use.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
23.0 nM [IC50]
3620.0 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ONON
Primary
ONON
Primary
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
The usual adult dosage for oral use is 450 mg of pranlukast hydrate (4 capsules) daily in two divided doses after each meal in the morning and evening. The dosage may be adjusted according to the patient's age and symptoms.
Route of Administration: Oral
In Vitro Use Guide
The activity of pranlukast was measured using calcium mobilization assay. HEK 293 cells stably expressing CysLT1 receptor and Gα16 protein were loaded with 2 uM Fluo-4 AM in Hanks balanced salt solution buffer. The compound was added to a solution, and after 10 min incubation at room temperature, 25 uL LTD4 was dispensed into the well using a FlexStation II microplate reader, and intracellular calcium change was recorded with an excitation wavelength of 485 nm and an emission wavelength of 525 nm. The IC50 for pranlukast was 23 nM.